By David Tuller, DrPH When I first began examining the PACE trial in detail, I turned to clinical trial experts to vet my concerns. One of them was biostatistician Bruce Levin, a professor at Columbia University's Mailman School of Public Health, to whom I was referred by a mutual colleague. ...

By David Tuller, DrPH I’ll be in Bristol later this week for the CFS/ME Research Collaborative’s annual conference. I was not welcome last year, since I was at that point engaged in harshly criticizing the organization for its unwillingness to acknowledge that its deputy chair had falsely accused me of ...

By David Tuller, DrPH Cochrane--formerly called the Cochrane Collaboration--is respected worldwide for its systematic reviews of medical treatments. These reviews are often cited as the definitive source of information about treatment efficacy and safety. In taking on the thankless task of assessing the data on commonly used interventions, Cochrane performs ...

By David Tuller, DrPH Jonathan Edwards, an emeritus professor of medicine at University College London, recently sent a letter to Professor Fiona Watt, executive chairwoman of the UK Medical Research Council. The MRC was the main funder of PACE and has continued to defend the trial and its conduct. In ...

By David Tuller, DrPH Last week, The Times ran an article about the open letter to The Lancet concerning the PACE trial, quickly followed by a piece in The BMJ. This morning, I e-mailed the following letter to Fiona Godlee, editor-in-chief of The BMJ and editorial director at BMJ. I ...